积分兑换
关注公众号
收藏产品
产品详情
分子别名（Synonym）
RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF
表达区间及表达系统（Source）
Human VEGF165, premium grade (VE5-H4210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
Predicted N-terminus: Ala 27
It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage.
GMP-VE5H23 is the GMP version of this VE5-H4210. These two proteins display indistinguishable performance profiles, thereby ensuring a seamless transition for end users from early preclinical stag to later clinical phases.Request for sequence蛋白结构（Molecular Characterization）
This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
偶联（Conjugate）
Unconjugated
内毒素（Endotoxin）
Less than 0.01 EU per μg by the LAL method.
宿主蛋白残留（Host Cell Protein）
0.5 ng/µg of protein tested by ELISA.
宿主核酸残留（Host Cell DNA）
0.02 ng/μg of protein tested by qPCR.
无菌（Sterility）
Negative
支原体（Mycoplasma）
Negative.
纯度（Purity）
95% as determined by SDS-PAGE.
95% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
质量管理控制体系（QMS）
产品展示
电泳（SDS-PAGE）
Human VEGF165, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human VEGF165, premium grade (Cat. No. VE5-H4210) is more than 95% and the molecular weight of this protein is around 42-60 kDa verified by SEC-MALS.
Report
活性（Bioactivity）-CELL BASE
Human VEGF165, premium grade (Cat. No. VE5-H4210) stimulates proliferation of 293F-NFAT/Luc-VEGFR2-3-7 cells. The specific activity of Human VEGF165, premium grade is＞8.00 x 10^5 IU/mg, which is calibrated against human vascular endothelial growth factor 165 WHO International Standard (NIBSC code: 02/286) (QC tested).
Protocol
Human VEGF165, premium grade (Cat. No. VE5-H4210) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 4.216-9.281 ng/mL (Routinely tested).
Protocol
Inhibition assay shows that the proliferation effect of Human VEGF165, premium grade (Cat. No. VE5-H4210) is inhibited by increasing concentration of anti-VEGF mAb (Avastin). The concentration of VEGF165 used is 20 ng/mL. The ED50 is 0.065-0.229 μg/mL (Routinely tested).
Protocol
Response to human VEGF165 protein (Fold).
The VEGFR2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (AcroBiosystems, Cat. No. VE5-H4210). The max induction fold was approximately 70 (Routinely tested).Protocol
活性（Bioactivity）-ELISA
Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 0.1 μg/mL (100 μL/well) can bind Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) with a linear range of 4-31 ng/mL (QC tested).
Protocol
Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a linear range of 10-156 ng/mL (Routinely tested).
Protocol
Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Bevacizumab and 0.5 μg/mL (100 μL/well) Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a half maximal inhibitory concentration (IC50) of 0.70 μg/mL (Routinely tested).
Protocol
活性（Bioactivity）-SPR
Anti-VEGFA Antibody, Human IgG1 captured on Protein A Chip can bind Human VEGF165, premium grade (Cat. No. VE5-H4210) with an affinity constant of 0.103 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
活性（Bioactivity）-BLI
Loaded bind Anti-VEGFA Antibody, Human IgG1 on AHC2 Biosensor, can bind Human VEGF165, premium grade (Cat. No. VE5-H4210) with an affinity constant of 53.8 pM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded bind Human NRP1, Fc Tag (Cat. No. NR1-H5252) on Protein A Biosensor, can bind Human VEGF165, premium grade (Cat. No. VE5-H4210) with an affinity constant of 17.3 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
稳定性（Stability）
The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG VEGF165.
用户评价 发表评论
背景介绍
前沿进展
药物研发进展 - 英文全称：
Vascular endothelial growth factor A
- 中文全称：
血管内皮生长因子A
- 种类：
- 上市药物数量：
48 详情
- 临床药物数量：
65 详情
- 最高研发阶段：
批准上市
法规支持文档 
联系我们 
促销与展览 - 抗体药物开发实用技术探讨线下论坛申请资料包
项目合作